B
BioIntervene
Developing non-addictive medicines for chronic pain and neurodegenerative disorders using selective adenosine A3 receptor agonists
About BioIntervene
BioIntervene, Inc. is a preclinical stage biopharmaceutical company focused on discovering and developing effective, non-addictive medicines for chronic pain, chronic inflammatory, and neurodegenerative disorders. Founded in 2014, the company leverages insights from research conducted at Saint Louis University and the National Institutes of Health (NIH). BioIntervene's pioneering work centers on the biology of adenosine A3 receptors, aiming to create first-in-class, selective adenosine A3 receptor agonists.
The company operates in the biopharmaceutical market, targeting healthcare providers, researchers, and pharmaceutical companies as its primary clients. BioIntervene's business model revolves around the research and development (R&D) of novel drug candidates, which are then licensed out or sold to larger pharmaceutical companies for further development and commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties from successful drug candidates.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2020 | $30M | $120M | MPM BioImpact | ↗ |
| EARLY VCEquity / VC | Mar 2019 | $3.1M | $12M | Undisclosed | — |
Growth signals
Latest recorded traffic for BioIntervene is 210 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
BioIntervene in the San Diego ecosystem
The BioIntervene office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
MPM BioImpact
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioIntervene on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioIntervene’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









